Boulder’s Nivalis Therapeutics files for $60 million stock offering

Denver Post – Boulder-based pharmaceutical company Nivalis Therapeutics has filed for an initial public stock offering to raise up to $60 million.

Nivalis is a clinical-stage company focused on treatments for cystic fibrosis.  Read more…